Romo 1/10 of the way to a blockbuster

Romosozumab generated $104 million in global sales through the first nine months of this year.

big sales mofo!

 

And the product will peak around $250-300 million.

 

My product peaks around 8" - 9"

 

corlanor or imlygic?

 

Global, how much was US.......?

 

Unfortunately CV issues will limit long term viability

 

Word is CV issues are real. Let’s see how long it takes to go public. Heard from an investigator..

 

Great work gumshoe. You should alert the FDA and EMA. They could use a super sleuth like yourself. Twerp.

Amgen’s EVENITY Rejected by EU Due to Cardiovascular Risks
https://www.docwirenews.com/docwire-pick/rheumatology-picks/amgens-evenity-rejected-by-eu-due-to-cardiovascular-risks/

ARCH study: Romosozumab data show increased cardiovascular risk
https://www.healio.com/endocrinology/bone-mineral-metabolism/news/online/%7Bb5d1ba58-35eb-45ce-9a7a-77689cec8e89%7D/arch-study-romosozumab-data-show-increased-cardiovascular-risk

 

Gumshoe here,
These are the pre market trials and EU results. I am talking real world in the marketplace. CV risks appear to be real and not limited to Latin America trial sites.
Big difference to writing physicians taking real patient risk not related to a trial. But we will see what post marketing surveys show.....